Bioventures 2014 L.P. Mpm Sells 61,640 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 61,640 shares of the company’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $0.93, for a total value of $57,325.20. Following the sale, the insider owned 5,538,600 shares of the company’s stock, valued at $5,150,898. This trade represents a 1.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Monday, November 17th, Bioventures 2014 L.P. Mpm sold 57,061 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.95, for a total value of $54,207.95.
• On Thursday, November 13th, Bioventures 2014 L.P. Mpm sold 90,951 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total transaction of $89,131.98.
• On Wednesday, November 12th, Bioventures 2014 L.P. Mpm sold 40,669 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.09, for a total transaction of $44,329.21.
• On Tuesday, November 11th, Bioventures 2014 L.P. Mpm sold 55,810 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total transaction of $63,623.40.
• On Monday, November 10th, Bioventures 2014 L.P. Mpm sold 48,570 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.18, for a total transaction of $57,312.60.
• On Friday, November 7th, Bioventures 2014 L.P. Mpm sold 68,480 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.11, for a total transaction of $76,012.80.
• On Thursday, November 6th, Bioventures 2014 L.P. Mpm sold 54,452 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total transaction of $65,886.92.
• On Wednesday, November 5th, Bioventures 2014 L.P. Mpm sold 47,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total value of $58,499.00.
• On Tuesday, November 4th, Bioventures 2014 L.P. Mpm sold 140,488 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total value of $171,395.36.
• On Monday, November 3rd, Bioventures 2014 L.P. Mpm sold 94,063 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total value of $121,341.27.

Werewolf Therapeutics Stock Down 0.5%

Shares of HOWL stock opened at $0.92 on Wednesday. The stock’s fifty day moving average price is $1.56 and its 200 day moving average price is $1.34. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $2.38. The company has a market cap of $44.42 million, a price-to-earnings ratio of -0.56 and a beta of 0.72. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. On average, research analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HOWL. Jane Street Group LLC purchased a new position in shares of Werewolf Therapeutics during the 2nd quarter valued at about $409,000. Citadel Advisors LLC purchased a new position in Werewolf Therapeutics during the third quarter valued at approximately $304,000. Vanguard Group Inc. raised its position in Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after acquiring an additional 109,796 shares in the last quarter. Marshall Wace LLP acquired a new position in Werewolf Therapeutics in the second quarter valued at approximately $113,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Werewolf Therapeutics in the 2nd quarter worth approximately $92,000. 64.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HOWL has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Zacks Research raised shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. JMP Securities reduced their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Citigroup reaffirmed a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Finally, Bank of America cut their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.